Physician profile
Fan Ye
NPI 1558715912
$5,152.22
in general payments reported to CMS, 2019-2025
14 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $82.96 · 2021: $273 · 2022: $1,457 · 2023: $1,685 · 2024: $301 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,809 · Food and Beverage: $1,314 · Education: $78.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,808.93 |
| Food and Beverage | $1,313.84 |
| Education | $78.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,374.31 | 2021-2022 | |
| Boston Scientific Corporation | $1,358.93 | 2023 | Watchman Access System |
| Medtronic, INC. | $1,346.16 | 2021-2025 | Cobalt Dr Mri Surescan, Selectsecure, Micra |
| Heartflow, INC. | $356.89 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $270.15 | 2019-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $160.59 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $85.16 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $38.85 | 2025 | Camzyos, Eliquis |
| Amgen INC. | $37.26 | 2024-2025 | Repatha, Repatha |
| Biosense Webster, INC. | $32.93 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.47 | 2020-2021 | |
| Pfizer INC. | $26.93 | 2025 | |
| Novo Nordisk INC | $24.06 | 2025 | Ozempic |
| Biotronik INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fan Ye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.